BIOA logo

BIOAGE LABS INC

BIOANASDAQ
πŸ† #3618 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track BIOA
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$161M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
99.3%
High
πŸ’΅FCF Margin
-1197.8%
Thin
βš–οΈP/S Ratio
18.7x
Expensive
Otter Score
52
Fair
No chart data available for BIOA.

Trading Snapshot

Day Range
β€”
52-Week Range
$4.24 – $25.96
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
37.6M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$298,000
P/E Ratio
-1.7
P/S Ratio
18.7x
EPS (TTM)
$-2.35
Dividend Yield
0.00%
Dilution (1yr)
+0.7%
BIOA logo

BIOAGE LABS INC

BIOA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9M
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$93Mβ–² +18.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$82Mβ–² +58.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
36.1Mβ–² +0.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$183Mβ–Ό βˆ’$162M YoY
StockOtter Β· stockotter.space

About BIOAGE LABS INC

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
52/100
Analyst data unavailable.

Latest News & Updates

News unavailable.